Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 9, Number 1—January 2003
Research

Cost Effectiveness of a Potential Vaccine for Human papillomavirus

Gillian D. Sanders*Comments to Author  and Al V. Taira*
Author affiliations: *Stanford University, Stanford, California, USA

Main Article

Table 2

Intermediate health outcomes of HPV vaccinationa,b

OutcomeHPV vaccinationNo vaccinationLifetime cases avertedNo. needed to vaccinate to prevent one case
HPV
1,460,699
1,684,954
224,255
9
SIL
417,549
530,259
112,710
18
Cervical cancer
13,374
16,690
3,316
600
Cervical-cancer deaths5,1216,4611,3401,484

aAssumes program that successfully administers a vaccine against high-risk HPV to the current U.S. cohort of 12-year-old girls.

bHPV, Human papillomavirus; SIL, squamous intraepithelial lesions.

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external